GlaxoSmithKline plc (GSK) 10% Owner Owns Stock Worth $0.28 million

GlaxoSmithKline plc (NYSE:GSK) finished Tuesday with a subtraction of -$0.09 to close at $38.13, a downside of -0.24 percent. An average of 3,917,100 shares of common stock have been traded in the last five days. There was a fall of -$0.20 in the past week. The last 20 days have seen an average of 3,953,540 shares traded, while the 50-day average volume stands at 3,540,792.

GSK stock has decreased by -6.86% in the last month. The company shares reached their 1-month lowest point of $37.80 on 10/06/21. With the stock rallying to its 52-week high on 08/18/21, shares of the company touched a low of $33.26 and a high of $42.68 in 52 weeks. In spite of this, the price is down -10.66% from the 52-week high.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Insider Transactions

140 days have passed since GlaxoSmithKline plc (GSK) last reported insider trading activity. GLAXOSMITHKLINE PLC, who is 10% Owner, most recently acquired $32,005,260 shares at $12.25 per share on May 20.

Valuation Metrics

GlaxoSmithKline plc (GSK) has a trailing price-to-earnings (P/E) ratio of 16.27, which compares with the 23.00 for the broader industry and 31.71 for the sector. This means investors are optimistic about the stock’s future prospects. In the last five years, GlaxoSmithKline plc’s PE ratio has ranged between 360.16 and 10.37. The stock’s beta is 0.70. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.14, the price-to-book (PB) ratio at 4.61, and the price-to-cash flow ratio at 63.73.

GlaxoSmithKline plc pays a $2.09 dividend per share annually. It offers a dividend yield of 5.48%. The company has a payout ratio of 51.50%. The company’s most recent quarterly dividend payment took place on Oct. 7, and it was $0.5230 a share, representing a down of -21.74 from $0.6367 last year. Its latest decrease dividend $0.1137 reported on Friday July 30 2021. Dividends have grown by -1.26% each year over the last three years.

GlaxoSmithKline plc will next go ex-dividend on 15-Nov. The next dividend payment GlaxoSmithKline plc will make is expected to be $0.482.

The quick ratio of GlaxoSmithKline plc for the three months ended June 29 was 0.50, and the current ratio was 0.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.33 and a total debt to equity ratio of 1.66 for the quarter ending June 29. On the profitability front, the trailing 12-month gross margin is 67.70% against a 5-year average of 65.9%. GlaxoSmithKline plc’s EBITDA margin for the year ending June 29 is 30.89%, while its operating margin for the same period stands at 19.10%. Its gross profit as reported stood at $28.76 billion compared to revenue of $43.78 billion.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, GlaxoSmithKline plc’s return on assets was 5.50%, compared to 4.9% over the last five years. In the past year, the return on investment has been 17.30%, and the 5-year average is 13.1%. Meanwhile, the return on equity (ROE) for the past 12 months has been 29.70% and the 5-year average holds at 124.0%. For the broader industry, ROE averaged -15.50 over the past year.

Earnings Surprise

The analyst consensus anticipated GlaxoSmithKline plc’s latest quarter earnings to come in at $0.51 per share, but it turned out to be $0.79, a 54.90% surprise. For the quarter, EBITDA amounted to $3.28 billion.

Technical Picture

From a technical analysis perspective, let’s take a brief look at GlaxoSmithKline plc (GSK) price momentum. RSI 9-day as of the close on 05 October was 32.57%, suggesting the stock is Neutral, with historical volatility in this time frame at 14.57%.

As of today, GSK’s price is $38.22 -0.52% or -$0.20 from its 5-day moving average. GSK is currently trading -5.90% lower than its 20-day SMA and -2.43% lower than its 100-day SMA. However, the stock’s current price level is -3.52% below the SMA50 and +3.03% above the SMA200.

The stochastic %K and %D were 21.76% and 20.01%, respectively, and the average true range (ATR) was 0.46. With the 14-day stochastic at 17.84% and the average true range at 0.47, the RSI (14) stands at 33.59%. The stock has reached -0.01 on the 9-day MACD Oscillator while the 14-day reading was at -0.31.

Analyst Ratings

Deutsche Bank upgraded GlaxoSmithKline plc (NYSE: GSK) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a a Sell.The consensus rating for GlaxoSmithKline plc (GSK) among analysts is Overweight. According to current brokerage recommendations, 2 brokerage firms advise that investors sell GSK, while 12 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 7 others rate it as a “buy”.

What is GSK’s price target for the next 12 months?

Analysts predict a range of price targets between $37.41 and $57.38, with a median target of $42.42. Taking a look at these predictions, the average price target given by analysts for GlaxoSmithKline plc (GSK) stock is $44.11.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam